Coral Laboratories Limited (524506) Fair Value & Analysis

Healthcare · IN · Market cap ₹1.4B

Below-average quality, screening 23% undervalued on our models.

What matters now

• Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality.
• Our model range runs from ₹546.40 (bear) to ₹974.04 (bull), base ₹779.23. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 48/100 (below-average quality) with medium evidence: read the verdict with care.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹218.89 – ₹988.45 · fair‑value band ₹546.40 – ₹974.04 · the ₹633.50 price screens below the ₹779.23 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Coral Laboratories Limited (524506) currently trades at ₹633.50, while our model-based Fair Value estimate is ₹779.23, implying the stock looks roughly 23.0% undervalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Coral Laboratories Limited generated revenue of ₹792M at a net margin of 15.2%. Revenue grew 63.5% year over year. Net debt stands at ₹29.6M. The stock trades on a trailing P/E of 11.1 (as of Jul 4, 2026). Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹546.40 (bear case) to ₹974.04 (bull case); at ₹633.50, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 76% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at 23%, 524506 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹780.57) versus Dividend Discount (₹15.48). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. The company offers antibiotics/antibacterial products, including antifungal, antiemetic, analgesics/antipyretic/antiinflammatory, antispasmodic, anticold, antiallergic, antiasthmatic, antidiabetic, antiemetics, anthelmentic, thyroid, and …

Full company description

Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. The company offers antibiotics/antibacterial products, including antifungal, antiemetic, analgesics/antipyretic/antiinflammatory, antispasmodic, anticold, antiallergic, antiasthmatic, antidiabetic, antiemetics, anthelmentic, thyroid, and antiprotozoal/antiamebic products; antimalarial drugs, antipsychotic drugs, gastro-intestinal drugs, kits, muscle relaxants, cough suppressant/expectorant products, cardiovascular medicines, oral antiseptic preparations, mouthwashes, calcium preparations, and appetizers; and nutritional, protein, and iron supplements, as well as other products. It also provides cephalosporin, beta lactam, and lyophilized injectable products; eye/ear/nose drops; nasal sprays and metered dose inhales; and large volume parenteral products. In addition, the company offers various nutraceutical products, such as dietary supplements, herbal/phytochemicals, multivitamins, and nutrients, as well as OTC products. It provides its products in various dosage forms, including tablets, capsules, low RH facilities, liquid orals, liquids and powders, dry syrups, drops, ointment and creams, gels and lotions, granules powders, injectables, nasal sprays, and suppositories. Coral Laboratories Limited was incorporated in 1994 and is headquartered in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Coral Laboratories Limited reported revenue of ₹859M in FY2026 versus ₹756M in FY2022, a compound +3.2%/yr. Reported net income was ₹164M in FY2026, compounding +16.0%/yr from FY2022.

Watch 524506: get an alert when its fair value changes →

Peer Group

Health Care · 2285 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)

Valuation Multiples vs Health Care median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.